DOCSLIB.ORG

Author Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Author Index Page numbers in italie8 refer to the bibliography Aaron, H. 564, 565 Abrams, W.B., Pocelinko, Adams, H. R., see Clarke, Aars,H. 313, 337, 378 R., Klausner,M., D.E. 104, 105,138 Aars,H., see Eide,J. 526, Hanauer,L., Whitman, Ader,R., see Brodie,D.A. 527,539 E.N. 170,247 131,135 Aas,K., Blegen,E. 68, 72 Abrams,W.B., Pocelinko, Adlerova,E., see Protiva, Abbab,A.G., see Hicks,D. R., Moe,R.A., Bates,H., M. 26,27,29,30,56 C. 593,624 Hanauer,L., Camacho, AdIin, E. V ., Channick, B. Abbott,E.C., GornaIl,A.G., S. 186,247 J. 502,513 SutherIand,D.J.A., Abrams, W.B., Solomon,H. AdIin,E. V., see Channick, Stiefel,M., Laidlaw,J.C. M. 236,247 B.J. 487, 489 506,513 Abrams, W., see Malmfors, Adlin, E. V ., see Marks, A. Abboud,F.M., Eckstein,J. T. 190, 203, 212, 213, D. 502,515 W. 214,247 257 Adriaensen,H., Vryens,R. Abboud,F.M., Eckstein,J. Abrams, W. B., see Solo­ 456, 457, 475 W., Pereda,S.A. 214, mon,H.M. 189,236, Aellig, W.H., Prichard,B. 247 260 N.C., Scales,B.A. 622 Abbs,E.T. 183,190,247 Abramson,F.B., Furst,C. Aellig, W.H., SameIi,K. 1., McMartin,C., Wade, Abbs, E. T., Dodd,M. G. 594,622 R. 205, 248 Afonso,A., see Kupchan, 195,247 Abreu,B.E., Richards,A. Abbs,E.T., Pycock,C.J. S.M. 549,568 B., Alexander, W.M., Agarwal,S.L., Bose,D. 196,247 Weaver,L.C. 551,553, 1I8,132 Abbs,E. T., Robertson,M.l. 556, 558, 565 Aghajanian,G.K., see 186, 194, 195, 196, 213, Aceto,M., Harris,L.S. Svensson, Th. 361,369, 247 124,132 394 Abbs, E. T., see Robertson, Achari,G., see Ahmad,M. Agre,C.L., see Helgen,L. M.L 195,260 222,248 33, 53 Abercrombie,G.F., Davies, Acheson,G.H., Moe,G.K. Agrest,A., see Smith,J.R. B.N. 183, 187, 247 61,72 67,68,76 Aberg,H., see Hansson,L. Acheson,G.H., Pereira,S. Ahearn,D.J., Grim,C.E. 607, 608, 629 A. 61,66,72 427, 465, 614, 615, 616, Ablad,B. 400, 401, 402, Acheson,G.H., see Krayer, 627 403,404, 413, 457, 607, O. 556,557,567 Ahlstrom,A.P., see Reilly, 608,627 Achor,R. W.P., see J.F. 152 Ablad,B., Ervik,M., Hall­ Quetsch,R.M. 123,152 Ahmad,M., Achari,G. 222 gren,J., Johnsson, G., Ackenheil,M., see Lydtin, 248 SolveIl,L. 592, 593, H. 596,601,602,625 Adam,H.M. 99,132 Ahmad,N., see Kahn,M. 594,622 M. 44,53 Ablad,B., Johnsson,G. Adam,H.M., Hye,H.K.A. 84, 100,132 Aisenbrey,G., see 400, 401, 406, 457 Adams,A.P., Clarke,T.N. McDonald,K.M. 528, Ablad,B., Johnsson,G., S., Edmonds-Seal,J., 542 Henning,M. 401, 402 Fi:iex,P., Prys-Roberts, Akashi,A., Chiba, T., 457 C., Roberts,J. 419, Kasahara,A. 417,458 Ablad,B., MeIlander,J. 420, 422, 465 Akashi,A., see Ueno,K. 400, 401, 406, 457 Adams,A.P., Clarke, T.N. 40, 58 Ablad,B., see Tibblin,G. S., Edmonds-Seal,J., Akhtar,N., see Franciosa, 596, 600, 627 Fi:iex,P., Prys-Roberts, J.A. 420,422,428,466 Abrams,D.L., see Miller, C., Roberts,J.G., 419, Akre,S., see Eide,J. 526, A.J. 415,462 420, 421, 465 527,539 644 Author Index Akutshu, U., see Ueda,E. Allen,J.G., East, P.B., Amery,A., Verstraete,M., 521,546 Francis,R.J., Haigh,J. BQssaert,H., Veriltre­ Alanis,J., see Crumpton, I. 210,248 ken,G. 587,588,621 C.W. 562,566 Allen,M.J., see Bencze,W. Amery,A.K.P.C., see Alarcon-Segovia,D. 416, L. 501,513 Parija,J. 486,492 609,627 Allen,M.J., see Chart,J.J. Amin,A.H., Crawford, Alarcon-Segovia,D ., 501,513 T.B., Gaddum,J.H. Osmundson,P.J. 415, Alles,G.A. 14,49 99, 132 416,458 Alleva,J.J. 268,285 Amsterdam,E.A., Couch, Alarcon-Segovia, D., Alimann,D., see Goodfried, N.P., Christlieb,R., Worthington,J. W., T.L. 529,532,540 Harrison,J.H., Crane, Ward,L.E., Wakim,K. Almgren,O. 278,285 C., Dobrzinsky,S. 524, G. 414, 416, 458 Almgren,O., Jonason,J. 537 Alderman, E. L., see 273,285 Amsterdam,E.A., Spann, Kerber,R.E. 601,625 Almgren,O., Lundborg,G. J.F., Mason,D. T., Aldin,E.V., Marks,A.D., 273,285 Zelis,R.F. 217, 218, Channick,B.J. 617, Almgren,O., Lundborg,P. 248 632 G., Stitzel,R.E. 273, Anagnoste,B., see Gold­ Aldrich"P.E., Diassi,P.A., 285 stein, M. 267, 268, Dickel,D.F., Dylion,C. Aloe,L., see Johnson,E.M. 276,289 M., Hance,P.D., Hueb­ 233,255 Andlm,N.E., Corrodi,H., ner,C.F., Korzun,B., Alper,M.H., Schmier,J. Ettlcs,M., Gustafsson, Kuehne,M.E., Liu,L. 112,132 E., Persson,H. 272, H., McPhi1lamy,H.B., Alper,M.H., see Krayer,O. 277,285 Robb,E. W., Roychaud­ 101, 146, 216, 217, 219, Anden,N.E., Corrodi,H., huri,D.K., Schlittler, E., 256 Fuxe,K., Hiikfelt,B., St.Andre,A.F., van Alpers,H.S., Shore,P.A. Hiikfelt, T., Rydin, C., Tamelen,E.E., Weisen­ 79, 97, 104,132 Svensson, T. 282, 285, born,F.L., Wenkert,E., Alpers,H.S., see Crout,J. 357, 361, 368, 370, 371, Wintersteiner, O. 25, R. 275,287 376, 377, 378 49 Alpers,H.S., see Shore,P. Anden,N.E., Engel,J., Aleksandrow,D.,·Wysz­ A. 275,284,295 Rubenson,A. 284, 285 nacka, W., Gajewski,J. Alps,B.J., see Archibald, Anden,N.E., Fuxe,K., 477,478,489 J.L. 46,49 Hiikfelt, T. 121, 132 Alexander, W.M., see Alstad,K.S., see Smirk, Anden,N.E., Grabowska, Abreu,B.E. 551,553, F.H. 78,155 M., Striimbom, W. 556, 558, 565 Althuis, T.H., Hess,H.J. 357, 361, 368, 371, 376, Alexandre,J.M., Chevil­ 455,475 377,378 lard, C., Menard,J., Altman,J., see Eighozi, Anden,N.E., Henning,M. Schmitt, H. 334, J.L. 531, 539 97, 104, 132, 274, 285 378 Altman,K.P., see Starke, Anden,N.E., Magnusson, Alexandre,J.M., see Che­ K. 310,393 T., Waldeck,B. 104, villard, C. 334, 335, Altura,B.M. 280,282, 132 381 285 Anden,N.E., Striimbom, Alexandre,J.M., see Fryd­ Altura,B.M., Zweifach,B. U., Svesson, T.H. 377, man,A. 373, 382 W. 215,248 378 Alge,ri,S., see Manara,L. Amakawa,A., see Shimazu, Anderson,C., Stone,T.W. f24,149 T. 102,154 369,378 Alimurung,M.M., Grajo, Amann,A., Schaefer,H. Anderson,E.G., see Baker, M.Z. 561, 565 553,565 R.G. 367,379 Alkalay,J., Bullard,J.C. Amaranath,L., Keller­ Anderson,G.H., see Stree­ 414,458 meyer, W.F. 429,465 ten,D.H.P. 533,545 AlIais,A., see Muller,G. Ambache,N., Perry, W.L. Anderson,J., Godfrey,B. 27,55 M., Robertson,P.A. E., Hill,D.M., Munro­ Allais,A., see Velluz,L. 66,73 Faure,A.D., Sheldon,J. 27,58,59 Ambani,L.M., Woert,M.H. 480,483,489 Allan,B.R., see McMartin, Van 118,132 Anderson,J.E.,Jr., see C.206, 207, 258, 575, Amery,A., Billiet,L., Conn,J. W. 506, 514 618 Fagard, R. 604, 622 Anderson,P.L., Hoillihan, AlIen,B.R., see Leishman, Amery,A., Verhiest, W., W.J., Manning,R.E. A. W.D. 597, 600, 625 Croonenberghs, J., 41,49 Allen,F.J., see Wasserman, Fagard, R. 455, 456, Anderson,R.A., Rae, W. A.J. 601, 627 475 430, 465 Author Index 645 Anderson,R.C., Herbert, Aoyagi, T., see Dmezawa, Arya,V.P., Grewal,R.S., P.N., Mulrow,P.J. H. 525, 526, 546 David,J., Kaul,C.L. 518, 537 Appel,J.B., Freedman, 46,49 Anderson,R.J., see Hen­ D.X. 125, 126,132 Ashley, C., see Solomon, rich,W.L. 443,469 Appel, W. 44, 49 H.M. 189,236,260 Anderson,R.W., see Thom­ Aprill,C.N., see Blackard, Askew,B.M. 119,123, son, G. R. 442, 479 W. G. 435, 436, 468, 132 Andersson,O., see Berg­ 613,628 Asma, W.J., see KraIt, T. lund,G. 594,622 Apthorp et al. 599 30,54 Andersson, R. 607, 628 Arakawa,K., Nakamura, Andre,A.F.St., see McPhil­ M. 522,537 Asmae,R., see Khan,I. lamy, H. B. 25, 55 Aramaki, Y., see Nagaoka, 211, 212, 256 Andreasen,F.V.V., see A. 403,462 Assali,N.S., Kaplan,J., Crout,J.R. 438,439, Aramendia,P., see Oeghenstein, S., 469, 612, 613, 628 Kaumann,A. 203, 256 Inymoto, R. 412, 458 Angeletti,P. D., Levi­ Aravindakshan, V., Gettes, Assan,C.J., see Krieger, Montalcini, R. 233, 248 L.S. 221,248 E.M. 528,542 Angeletti,P. D., Levi­ Arcari,G., Bernardi,L., Assaykeen, T.A., see Passo, Montalcini,R., Caramia, Bosisio,G., Coda,S., S. S. 602, 625 F. 233,248 Fregnan,G.B., Glasser, Asselin,J., see Boucher,R. Angeletti,P.D., see Cara- A.H.
Load more

Recommended publications
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, And
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2012 Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines Ethan Hamilton McIlhenny Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation McIlhenny, Ethan Hamilton, "Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines" (2012). LSU Doctoral Dissertations. 2049. https://digitalcommons.lsu.edu/gradschool_dissertations/2049 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr.
    [Show full text]
  • Current Neuropharmacology, 2019, 17, 108-128 REVIEW ARTICLE
    108 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2019, 17, 108-128 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Ayahuasca: Psychological and Physiologic Effects, Impact Factor: Pharmacology and Potential Uses in Addiction and 4.068 Mental Illness BENTHAM SCIENCE Jonathan Hamilla, Jaime Hallaka,b, Serdar M. Dursuna and Glen Bakera,* aDepartment of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada; bDepartment of Neurosciences and Behavior and National Institute of Science and Technology (Translational Medicine), Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil Abstract: Background: Ayahuasca, a traditional Amazonian decoction with psychoactive proper- ties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experi- ences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use it routinely to foster a spiritual experience. More recently, it is being used in Europe and North America, not only for religious or healing reasons, but also for recreation. Objective: To review ayahuasca’s behavioral effects, possible adverse effects, proposed mechanisms A R T I C L E H I S T O R Y of action and potential clinical uses in mental illness. Received: July 26, 2017 Method: We searched Medline, in English, using the terms ayahuasca, dimethyltryptamine, Banis- Revised: November 07, 2017 teriopsis caapi, and Psychotria viridis and reviewed the relevant publications.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Chemical Composition of Traditional and Analog Ayahuasca
    Journal of Psychoactive Drugs ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ujpd20 Chemical Composition of Traditional and Analog Ayahuasca Helle Kaasik , Rita C. Z. Souza , Flávia S. Zandonadi , Luís Fernando Tófoli & Alessandra Sussulini To cite this article: Helle Kaasik , Rita C. Z. Souza , Flávia S. Zandonadi , Luís Fernando Tófoli & Alessandra Sussulini (2020): Chemical Composition of Traditional and Analog Ayahuasca, Journal of Psychoactive Drugs, DOI: 10.1080/02791072.2020.1815911 To link to this article: https://doi.org/10.1080/02791072.2020.1815911 View supplementary material Published online: 08 Sep 2020. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ujpd20 JOURNAL OF PSYCHOACTIVE DRUGS https://doi.org/10.1080/02791072.2020.1815911 Chemical Composition of Traditional and Analog Ayahuasca Helle Kaasik a, Rita C. Z. Souzab, Flávia S. Zandonadib, Luís Fernando Tófoli c, and Alessandra Sussulinib aSchool of Theology and Religious Studies; and Institute of Physics, University of Tartu, Tartu, Estonia; bLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil; cInterdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO), School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil ABSTRACT ARTICLE HISTORY Traditional ayahuasca can be defined as a brew made from Amazonian vine Banisteriopsis caapi and Received 17 April 2020 Amazonian admixture plants. Ayahuasca is used by indigenous groups in Amazonia, as a sacrament Accepted 6 July 2020 in syncretic Brazilian religions, and in healing and spiritual ceremonies internationally.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • 9719087.Pdf (3.190Mb)
    US009719087B2 a2) United States Patent (0) Patent No.: US 9,719,087 B2 Olson et al. (45) Date of Patent: *Aug. 1, 2017 (54) MICRO-RNA FAMILY THAT MODULATES A61LK 39/3955 (2013.01); AGLK 45/06 FIBROSIS AND USES THEREOF (2013.01); A6IL 31/08 (2013.01); AGIL 31/16 (2013.01); C12N 9/16 (2013.01); C12N (71) Applicant: THE BOARD OF REGENTS, THE 15/8509 (2013.01); AOIK 2207/30 (2013.01); UNIVERSITY OF TEXAS SYSTEM, AOIK 2217/052 (2013.01); AOLK 2217/075 Austin, TX (US) (2013.01); AOIK 2217/15 (2013.01); AOIK 2217/206 (2013.01); AOIK 2227/105 (72) Inventors: Erie N. Olson, Dallas, TX (US); Eva (2013.01); AOIK 2267/0375 (2013.01); AIL van Rooij, Utrecht (NL) 2300/258 (2013.01); A6IL 2300/45 (2013.01); : AOIL 2420/06 (2013.01); C12N 2310/113 (73) Assignee: THE BOARD OF REGENTS, THE (2013.01); CI2N 2310/141 (2013.01); CI2N UNIVERSITY OF TEXAS SYSTEM, 2310/315 (2013.01); C12N 2310/321 Austin, TX (US) (2013.01); C12N 2310/346 (2013.01); C12N (*) Notice: Subjectto any disclaimer, the termbe this (013.01ars orb01301CDN US.C.patent154(b)is extendedby 0 ordays.adjusted under 2320/32 (2013.01);4 . CI2N 2330/10yor(2013.01) (58) Field of Classification Search This patent is subject to a terminal dis- CPC vieceeceseeseeeeeeee C12N 15/113; C12N 2310/141 claimer. See application file for complete search history. — (21) Appl. No.: 14/592,699 (56) References Cited (22) Filed: Jan. 8, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 7,232,806 B2 6/2007 Tuschlet al.
    [Show full text]